Table 2.
Ongoing clinical trials on PARP-i in pancreatic cancer.
| PARP-i | Clinical Trial | Phase | Patient Population | Somatic Mutations/Germline PVs | Treatment Arm(s) |
|---|---|---|---|---|---|
| Olaparib | NCT04548752 | 2 | Pancreatic cancer | BRCA1/2 | Olaparib + pembrolizumab |
| NCT04005690 | 1 | Pancreatic cancer | nd | Olaprib + Cobimetinib | |
| NCT02498613 | 2 | Advanced Solid Tumors | nd | Olaparib + cediranib | |
| NCT03162627 | 1 | Solid Tumors | nd | Olaparib + selumetinib | |
| NCT03842228 | 1 | Advanced Solid Tumors | ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, POLD1, PP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, XRCC2, PTEN, PIK3CA | Olaparib + durvalumab + Copalinsib | |
| NCT02511223 | 2 | Pancreatic cancer | BRCAness | Olaparib alone | |
| NCT02677038 | 2 | Pancreatic cancer | Somatic BRCA mutation, Fanconi anemia genes, ATM or RAD51 mutations | Olaparib alone | |
| NCT02576444 | 2 | Solid tumors | ATM, CHK2, MRN (MRE11/NBS1/RAD50), CDKN2A/B, APOBEC, IDH1/IDH2, TP52, KRAS, PTEN, PIK3CA, AKT, or ARID1A | Olaparib + AZD1775 OR AZD5363 OR AZD6738 | |
| Rucaparib | NCT03140670 | 2 | Pancreatic cancer | BRCA 1/2 or PALB2 | Maintenance after platino-based chemo |
| NCT03337087 | 1–2 | Pancreatic, colorectal, gastroesophageal, or biliary cancer | BRCA 1/2 or PALB2 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib | |
| NCT04171700 | 2 | Solid Tumors | BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. | Rucaparib alone | |
| Veliparib | NCT02890355 | 2 | Pancreatic cancer | nd | FOLFIRI or mFOLFIRI + Veliparib as II Line |
| NCT01585805 | 2 | Pancreatic cancer | BRCA1/2 or PALB2 Germline PV | Gemcitabine + Cisplatin with or without veliparib or veliparib wlone | |
| NCT02723864 | 1 | Solid tumors | nd | M6620 (ATR inhibitor) + veliparib + cisplatin | |
| Niraparib | NCT03601923 | 2 | Pancreatic cancer | Germline PVs or somatic mutation of one of these: BRCA1/2, PALB2, CHECK2 or ATM | Niraparib alone |
| NCT04409002 | 2 | Pancreatic cancer | nd | Niraparib + Dostarlimab + RT | |
| NCT03553004 | 2 | Pancreatic cancer | DDR family mutation | Niraparib alone | |
| NCT04493060 | 2 | Pancreatic cancer | BRCA1/2 or PALB2 | Niraparib + Dostarlimab | |
| NCT03404960 | 1–2 | Pancreatic cancer | nd | Niraparib + Nivolumab or Ipilimumab after platinum-based chemotherapy | |
| NCT03207347 | 2 | Solid tumors | ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC | Niraparib | |
| NCT03209401 | 1 | Solid tumors | ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC | Niraparib + carboplatin | |
| Talazoparib | NCT02286687 | 2 | Solid tumors | Somatic BRCA1 or BRCA2; germline BRCA, ATM, PALB2, Fanconi Anemia genes, ARID1A, MER11, RAD50, NBS1, ATR; amplification of EMSY | Talazoparib |
| NCT03565991 | 2 | Solid tumors | ATM or BRCA | Avelumab and talazoparib | |
| Fluzoparib | NCT04300114 | 3 | Pancreatic cancer | Germline BRCA/PALB2 | Maintenance after platinum |
| Prexasertib | NCT02873975 | 2 | Solid tumors | MYC amplification, Rb loss, FBXW7 mutation, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHK2, the Fanconi anemia pathway genes, CCNE1 amplification of 6-fold or greater, or other genomic or somatic mutation in a known HR gene | Prexasertib (CHK inhibitor) |
| NCT03057145 | 1 | Solid tumors | nd | Prexasertib + olaparib | |
| BTT-114 | NCT02950064 | 1 | Pancreatic, breast, ovarian, or prostate cancer | BRCA or other DNA repair mutations, such as ATM, CHEK2, PALB2, and RAD51D | BTT-114, a novel platino product |
| ABT-144 | NCT01489865 | 1 | Pancreatic cancer | BRCA1/2 or PALB2 or FANC mutation or family history | ABT-144 + mFOLFOX6 |
| AZD0156 | NCT02588105 | 1 | Solid tumors | nd | (ATM/ATR inhibitor) Alone or in combination |
| M6620 (VX-970) | NCT02595931 | 1 | Solid tumors | nd | M6620 + irinotecan |
| AZD6738 | NCT03682289 | 2 | Renal, urothelial or pancreatic cancer | ATM or ARID1A | AZD6738 (ATR inhibitor) +/− olaparib |
| NCT02223923 | 1 | Solid tumor | nd | AZD6738 (ATR inhibitor) + radiotherapy | |
| NCT02630199 | 1 | Solid tumors | nd | AZD6738 (ATR inhibitor) + paclitaxel | |
| NCT03669601 | 1 | Solid tumor | nd | AZD6738 (ATR inhibitor) + Gemcitabine | |
| Ceralasertib | NCT02264678 | 1–2 | Solid tumors | ATM and BRCA evaluation | Ceralasertib +/− other drugs |
| BAY1895344 | NCT03188965 | 1 | Solid tumors | ATM or other DDR defects | BAY1895344 (ATR inhibitor) |
| NCT04514497 | 1 | Solid tumors | ATM and other DDR defects | BAY1895344 (ATR inhibitor) + irinotecan |